Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study
Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study
The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life.
The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments.
Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation.
The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.
Inclusion Criteria:
Exclusion Criteria:
dario.diperri@saintluc.uclouvain.be+32 2 764 47 52
Belgica.kce@saintluc.uclouvain.be+32 2 764 82 75
Aalst, 9300, Belgium
radiotherapie@azorg.be+32 53 72 86 66
+32 65 61 44 86
radiotherapie.brugge@azsintjan.be+32 50 45 28 00
accueil.cons.radiotherapie@hubruxelles.be+32 2 541 38 00
balie-radiotherapie@uzbrussel.be+32 2 477 60 41
+32 2 764 47 52
+32 89 80 83 30
secretariaat.radonco@azstlucas.be+32 9 224 66 20
secretariaat.radiotherapie@uzgent.be+32 9 332 30 15
+32 60 11 12 13
+32 11 33 79 79
radiotherapie@azgroeninge.be+32 56 63 39 03
+32 64 23 41 88
+32 16 34 76 00
radiotherapie@chuliege.be+32 4 323 75 96
+32 15 89 29 80
+32 71 92 09 52
secretariat.radiotherapie@chmouscron.be+32 56 85 83 60
+32 81 72 05 25
+32 51 23 75 82
+32 2 614 25 40
+32 2 614 37 26
+32 87 21 24 22
secretariaat@iridiumnetwerk.be+32 3 443 37 37